Andrew J Rowan
Overview
Explore the profile of Andrew J Rowan including associated specialties, affiliations and a list of published articles.
Author names and details appear as published. Due to indexing inconsistencies, multiple individuals may share a name, and a single author may have variations. MedLuna displays this data as publicly available, without modification or verification
Snapshot
Snapshot
Articles
20
Citations
7777
Followers
0
Related Specialties
Top 10 Co-Authors
Top 10 Co-Authors
Published In
Published In
Affiliations
Affiliations
Soon will be listed here.
Recent Articles
1.
Hynds R, Huebner A, Pearce D, Hill M, Akarca A, Moore D, et al.
Nat Commun
. 2024 May;
15(1):4653.
PMID: 38821942
Patient-derived xenograft (PDX) models are widely used in cancer research. To investigate the genomic fidelity of non-small cell lung cancer PDX models, we established 48 PDX models from 22 patients...
2.
Hynds R, Ben Aissa A, Gowers K, Watkins T, Bosshard-Carter L, Rowan A, et al.
Int J Cancer
. 2018 Mar;
143(1):160-166.
PMID: 29569246
Pre-clinical non-small cell lung cancer (NSCLC) models are poorly representative of the considerable inter- and intra-tumor heterogeneity of the disease in patients. Primary cell-based in vitro models of NSCLC are...
3.
McGranahan N, Rosenthal R, Hiley C, Rowan A, Watkins T, Wilson G, et al.
Cell
. 2017 Nov;
171(6):1259-1271.e11.
PMID: 29107330
Immune evasion is a hallmark of cancer. Losing the ability to present neoantigens through human leukocyte antigen (HLA) loss may facilitate immune evasion. However, the polymorphic nature of the locus...
4.
Lopez-Garcia C, Sansregret L, Domingo E, McGranahan N, Hobor S, Birkbak N, et al.
Cancer Cell
. 2017 Jan;
31(1):79-93.
PMID: 28073006
Chromosomal instability (CIN) contributes to cancer evolution, intratumor heterogeneity, and drug resistance. CIN is driven by chromosome segregation errors and a tolerance phenotype that permits the propagation of aneuploid genomes....
5.
de Bruin E, McGranahan N, Mitter R, Salm M, Wedge D, Yates L, et al.
Science
. 2014 Oct;
346(6206):251-6.
PMID: 25301630
Spatial and temporal dissection of the genomic changes occurring during the evolution of human non-small cell lung cancer (NSCLC) may help elucidate the basis for its dismal prognosis. We sequenced...
6.
Gulati S, Martinez P, Joshi T, Birkbak N, Santos C, Rowan A, et al.
Eur Urol
. 2014 Jul;
66(5):936-48.
PMID: 25047176
Background: Candidate biomarkers have been identified for clear cell renal cell carcinoma (ccRCC) patients, but most have not been validated. Objective: To validate published ccRCC prognostic biomarkers in an independent...
7.
Gerlinger M, Horswell S, Larkin J, Rowan A, Salm M, Varela I, et al.
Nat Genet
. 2014 Feb;
46(3):225-233.
PMID: 24487277
Clear cell renal carcinomas (ccRCCs) can display intratumor heterogeneity (ITH). We applied multiregion exome sequencing (M-seq) to resolve the genetic architecture and evolutionary histories of ten ccRCCs. Ultra-deep sequencing identified...
8.
Dewhurst S, McGranahan N, Burrell R, Rowan A, Gronroos E, Endesfelder D, et al.
Cancer Discov
. 2014 Jan;
4(2):175-185.
PMID: 24436049
Unlabelled: The contribution of whole-genome doubling to chromosomal instability (CIN) and tumor evolution is unclear. We use long-term culture of isogenic tetraploid cells from a stable diploid colon cancer progenitor...
9.
Gerlinger M, Quezada S, Peggs K, Furness A, Fisher R, Marafioti T, et al.
J Pathol
. 2013 Oct;
231(4):424-32.
PMID: 24122851
The recognition of cancer cells by T cells can impact upon prognosis and be exploited for immunotherapeutic approaches. This recognition depends on the specific interaction between antigens displayed on the...
10.
Martinez P, Birkbak N, Gerlinger M, McGranahan N, Burrell R, Rowan A, et al.
J Pathol
. 2013 May;
230(4):356-64.
PMID: 23716380
Intratumour heterogeneity (ITH) may foster tumour adaptation and compromise the efficacy of personalized medicine approaches. The scale of heterogeneity within a tumour (intratumour heterogeneity) relative to genetic differences between tumours...